Trevi Therapeutics, Inc. (TRVI): Price and Financial Metrics


Trevi Therapeutics, Inc. (TRVI)

Today's Latest Price: $2.89 USD

0.13 (-4.30%)

Updated Jan 20 6:55pm

Add TRVI to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 239 in Medical - Pharmaceuticals

See all "A" rated Strong Buy stocks

TRVI Stock Price Chart Interactive Chart >

Price chart for TRVI

TRVI Price/Volume Stats

Current price $2.89 52-week high $8.50
Prev. close $3.02 52-week low $1.33
Day low $2.62 Volume 646,900
Day high $3.38 Avg. volume 104,867
50-day MA $3.00 Dividend yield N/A
200-day MA $3.78 Market Cap 53.12M

Trevi Therapeutics, Inc. (TRVI) Company Bio


Trevi Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of treatment for neurologically mediated conditions. It focuses on the formulation of nalbuphine ER, which use to treat chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis, and levodopa-induced dyskinesia in patients with Parkinson's disease. The company was founded by Thomas R. Sciascia and Jennifer L. Good on March 17, 2011 and is headquartered in New Haven, CT.


TRVI Latest News Stream


Event/Time News Detail
Loading, please wait...

TRVI Latest Social Stream


Loading social stream, please wait...

View Full TRVI Social Stream

Latest TRVI News From Around the Web

Below are the latest news stories about Trevi Therapeutics Inc that investors may wish to consider to help them evaluate TRVI as an investment opportunity.

Trevi Therapeutics Announces Third Quarter 2020 Financial Results and Business Update

PRISM Trial of Haduvio™ for Severe Pruritus in Patients with Prurigo Nodularis  Exceeds Halfway Enrollment MilestonePhase 2 Chronic Cough Trial in Patients with IPF Enrolled First New Subject Post-COVID-19 RestrictionsCash Position Expected to Fund Operations into the First Half of 2022NEW HAVEN, Conn., Nov. 11, 2020 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company focused on the development and commercialization of Haduvio™ (nalbuphine ER) to treat serious neurologically mediated conditions, today announced financial results for the quarter ended September 30, 2020, as well as business updates.“We are pleased with the continued progress of our clinical development programs,” said Jennifer L. Good, President and CEO of Trevi Therap...

Yahoo | November 11, 2020

Trevi Therapeutics, Inc. to Host Earnings Call

NEW YORK, NY / ACCESSWIRE / November 11, 2020 / Trevi Therapeutics, Inc.

Yahoo | November 11, 2020

Trevi Therapeutics to Present at Stifel Healthcare Conference

NEW HAVEN, Conn., Nov. 10, 2020 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company focused on the…

GlobeNewswire | November 10, 2020

Trevi Therapeutics to Report Q3 2020 Financial Results on November 11

Conference Call and Webcast to be Held at 4:30 p.m. ET

GlobeNewswire | November 4, 2020

Trevi Therapeutics to Present at H.C. Wainwright Global Investment Conference

NEW HAVEN, Conn., Sept. 09, 2020 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company focused on the development and commercialization of Haduvio™ (nalbuphine ER) to treat serious neurologically mediated conditions, today announced that management will present a Company overview, as well as host virtual investor meetings, at the 2020 H.C. Wainwright Global Investment Conference on September 16, 2020: Presentation Time: 3:00 p.m. ETA live webcast of the presentation can be accessed by visiting ‘News & Events’ in the ‘Investors & News’ section on the Company's website at www.trevitherapeutics.com. An archived replay of the webcast will also be available for 30 days on the Company's website following the conference.The Company’s corporate...

Yahoo | September 9, 2020

Read More 'TRVI' Stories Here

TRVI Price Returns

1-mo 7.04%
3-mo -16.95%
6-mo -44.53%
1-year -44.10%
3-year N/A
5-year N/A
YTD 19.42%
2020 -35.47%
2019 N/A
2018 N/A
2017 N/A
2016 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.7286 seconds.